In this second set of a comprehensive four-part series of Homerun Slides on SGLT-2 inhibitors, we review some of the data of the second and third approved SGLT-2 inhibitors in the U.S., dapagliflozin (Farxiga) and empagliflozin (Jardiance), along with the Durability and Limitations of this drug class…. To download this …

In this first of a series of four sets of Homerun Slides, we review the basics of SGLT-2 inhibitors incuding Mode of Action, and Efficacy. and then look at how Canagliflozin has worked in poorly controlled type 2 diabetes patients…. To download the complete set in PowerPoint (.ppt) format, just …

I am sure many of you have received an email or Facebook post to participate in the ALS Ice Bucket Challenge. I am amazed by the number of people who will actually have a bucket of ice poured over their heads, yet will not take the time to check their …

MODY, cystic fibrosis, and Wolfram syndrome all have something in common. Believe it or not, they are all a form of diabetes. This week, our Clinical Text from the Handbook of Diabetes looks at these and other types or non-traditional causes of diabetes. Our Homerun Slides focus on how to …

Diabetes is a huge and growing problem, and the costs to society are high and escalating. In the Middle East and North Africa, 1 in 10 adults has diabetes. The Top 5 countries for prevalence in this region are: Saudi Arabia, Kuwait, Qatar, bahrain, and the united Arab Emirates. To …

  In this week’s Homerun Slides, Dr. Stanley Schwartz continues his exploration of a beta-cell centric classification model for diabetes and includes a detailed diagram explanation featuring the Egregious Eleven….

Rudy Bilous, MD, FRCP Richard Donnelly, MD, PHD, FRCP, FRACP   Maturity-onset diabetes of the young Maturity-onset diabetes of the young (MODY) owes its name to a time when diabetes was defined by age of onset. The nomenclature has stuck, however, and MODY defines usually non-insulin dependent diabetes occurring before the age …

Recently JARDIANCE (Empagliflozin) was approved for use, making it the third in this new class of medications. The first two, Invokana (canagiflozin) and Farxiga (dapagliflozin), have had relatively good acceptance into the marketplace especially with the financial ease they have established to get patients to use the medication. There are …

It is always interesting when two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes. Our own advisory board endocrinologist, Stanley Schwartz, is a good …

It is always interesting when you two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes. I had the opportunity to review a conversation that John …